Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis.

Screening with multicancer early-detection blood tests did not significantly reduce the incidence of stage III or IV cancers after three rounds in a large randomized trial.

• Why it matters: Determining whether blood-based early detection can improve cancer outcomes is crucial for developing effective screening strategies and reducing late-stage diagnoses.
• What they did: Researchers conducted a randomized controlled trial with over 142,000 participants aged 50 to 77 in England, comparing three rounds of blood-based screening plus usual care to usual care alone, measuring stage III or IV cancer incidence.
• The result: The incidence rate of stage III or IV cancers was similar between groups (IRR 1.03; P=0.63), and the rate of stage IV cancers after screening was slightly lower in the intervention group (IRR 0.86; 95% CI, 0.74 to 1.00), suggesting limited short-term benefit.